Safety of switching to nevirapine-based highly active antiretroviral therapy at elevated CD4 cell counts in a resource-constrained setting.
Kumarasamy
N
N
Venkatesh
Kartik K
KK
Devaleenal
Bella
B
Palanivel
Vidhya
V
Cecelia
Anitha J
AJ
Muthu
Sundaram
S
Yepthomi
Tokugha
T
Mayer
Kenneth H
KH
Flanigan
Timothy
T
D000328:Adult; D000480:Alkynes; D023241:Antiretroviral Therapy, Highly Active; D048588:Benzoxazines / Q000627:therapeutic use; D018791:CD4 Lymphocyte Count; D056486:Chemical and Drug Induced Liver Injury; D003365:Costs and Cost Analysis; D003521:Cyclopropanes; D005260:Female; D006678:HIV; D015658:HIV Infections / Q000188:drug therapy* / Q000191:economics / Q000276:immunology; D006801:Humans; D007194:India; D008099:Liver / Q000503:physiopathology; D008107:Liver Diseases / Q000503:physiopathology; D008297:Male; D019829:Nevirapine / Q000009:adverse effects / Q000191:economics / Q000627:therapeutic use*; D011446:Prospective Studies; D018894:Reverse Transcriptase Inhibitors / Q000627:therapeutic use*; D016896:Treatment Outcome
D000480:Alkynes; D048588:Benzoxazines; D003521:Cyclopropanes; D018894:Reverse Transcriptase Inhibitors; D019829:Nevirapine; C098320:efavirenz